| Market Capitalization (Millions $) |
1,063 |
| Shares
Outstanding (Millions) |
76 |
| Employees |
955 |
| Revenues (TTM) (Millions $) |
62 |
| Net Income (TTM) (Millions $) |
-114 |
| Cash Flow (TTM) (Millions $) |
28 |
| Capital Exp. (TTM) (Millions $) |
5 |
Zymeworks Inc
Zymeworks Inc is a biopharmaceutical company that primarily focuses on the development of multifunctional biotherapeutics in the areas of immuno-oncology, oncology, and autoimmune disorders. Their proprietary platforms, Azymetric and EFECT, enable the creation of highly differentiated and optimized bi-specific and multi-specific antibodies.
The Azymetric platform utilizes a unique approach that enables the engineering of antibodies to effectively target two different antigens simultaneously. This platform creates symmetrical antibodies that bind to both antigens with high affinity in a stable configuration, which provides superior disease-fighting capabilities. The Azymetric technology also allows for the creation of bi- and multi-specific antibodies with longer half-lives and reduced immunogenicity compared to traditional antibody therapies.
EFECT is a separate bi-specific antibody platform that is designed to activate the immune system by selectively targeting T-cell receptors on tumor cells. EFECT-engineered antibodies are created by fusing two monoclonal antibodies, one of which binds directly to tumor cells, and the other is designed to engage T-cells.
Zymeworks Inc has a portfolio of product candidates in various stages of development, including zanidatamab (ZYBRESTAT), a bi-specific antibody for the treatment of advanced solid tumors, and ZW25, a bi-specific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in many human cancers.
The company has partnerships and collaborations with other biopharmaceutical companies and research organizations, including Merck, Eli Lilly, Celgene, Kite Pharma, and ImmunoGen. They have also received funding from venture capitalists, investors, and government agencies.
Zymeworks Inc was founded in 2003 and is headquartered in Vancouver, British Columbia, Canada. The company has a workforce of over 400 employees, including experienced scientists, engineers, and clinicians. Zymeworks Inc aims to transform the lives of people living with serious diseases by advancing the science of biotherapeutics.
Company Address: 108 Patriot Drive, Suite A Middletown 19709 DE
Company Phone Number: 274-8744 Stock Exchange / Ticker: NASDAQ ZYME
|
1.24%